%0 Case Reports
%T Central nervous system relapse after combination therapy including polatuzumab vedotin in patients with diffuse large B-cell lymphoma.
%A Hori Y
%A Hosoi H
%A Mushino T
%A Okabe Y
%A Sakaki A
%A Yoshida K
%A Tochino Y
%A Yamashita Y
%A Sonoki T
%J Leuk Res Rep
%V 21
%N 0
%D 2024
%M 38939513
暂无%R 10.1016/j.lrr.2024.100467
%X Preventing central nervous system (CNS) relapse is a major challenge in the treatment of diffuse large B-cell lymphoma (DLBCL). However, no previous studies have examined the efficacy of polatuzumab vedotin (PV)-containing regimens in preventing CNS relapse in patients with DLBCL. Here, we report two cases of CNS relapse after PV-containing chemotherapy for DLBCL. CNS relapse developed during combination therapy with PV, bendamustine, and rituximab (PV-BR) in one patient and six months after PV-BR in the other patient. PV-containing chemotherapy may be ineffective as a prophylaxis against CNS relapse; therefore, additional strategies for preventing CNS relapse in DLBCL patients are required.